Increasing the price of cigarettes can reduce smoking substantially by discouraging initiation among youths and young adults, prompting quit attempts, and reducing average cigarette consumption among those who continue to smoke (1) (2) (3) . Increasing cigarette excise taxes is one of the most effective tobacco control policies because it directly increases cigarette prices, thereby reducing cigarette use and smoking-related death and disease (1) . All states and the District of Columbia (DC) impose an excise tax on cigarettes (1) . Because many states increased their cigarette excise taxes in 2009, CDC conducted a survey of these tax increases. For this report, CDC reviewed data contained in a legislative database to identify cigarette excise tax legislation that was enacted during 2009 by the 50 states and DC. During that period, 15 states (including DC), increased their state excise tax on cigarettes, increasing the national mean from $1.18 per pack in 2008 to $1.34 per pack in 2009. However, none of the 15 states dedicated any of the new excise tax revenue by statute to tobacco control. Additionally, for the first time, two states (Connecticut and Rhode Island) had excise tax rates of at least $3.00 per pack. Additional increases in cigarette excise taxes, and dedication of all resulting revenues to tobacco control and prevention programs at levels recommended by CDC, could result in further reductions in smoking and associated morbidity and mortality (2, 4) .
Cigarettes and other tobacco products are taxed by federal, state, and local governments in various ways, including excise taxes, which typically are levied per pack of 20 cigarettes (1) . State cigarette excise tax rates are set by legislation, are contained in state statutes, and usually are collected before the point of sale (i.e., from manufacturers, wholesalers, or distributors), as denoted by a tax stamp. Forty-four states and DC also levy state sales taxes on the retail sale of cigarettes (5) .
State cigarette excise tax data for this report were obtained from CDC's State Tobacco Activities Tracking and Evaluation (STATE) system database, which contains tobacco-related epidemiologic and economic data and information on state tobacco-related legislation. Data are collected quarterly from an online legal research database of state laws, analyzed, coded, and transferred into the STATE system. The STATE system contains information on state laws on excise taxes for cigarettes in effect since the fourth quarter of 1995.
All states and DC impose an excise tax on cigarettes (1) (Figure 1 ). During 2009, cigarette excise tax increases were enacted and took effect in 15 states: Arkansas, Connecticut, Delaware, DC, Florida, Hawaii, Kentucky, Mississippi, New Hampshire, New Jersey, North Carolina, Pennsylvania, Rhode Island, Vermont, and Wisconsin (Table) . No state decreased its excise tax. The increases ranged from $0.10 per pack in North Carolina to $1.00 per pack in Connecticut, Florida, and Rhode Island. For states with an excise tax increase in 2009, the mean increase was $0.52 per pack. The increases resulted in Connecticut and Rhode Island becoming the first two states with a cigarette excise tax of at least $3.00 per pack (Table) . Additionally, Hawaii included a provision in the state law that will increase the state cigarette excise tax by $0.20 per year in July 2010 and 2011, bringing the state tax to $3.00 per pack.
The national mean cigarette excise tax among all states increased from $1.18 per pack in 2008 to $1.34 per pack in 2009. South Carolina had the lowest state cigarette excise tax in the United States, at $0.07 per pack, and Rhode Island had the highest, at $3.46 per pack (Table) . Among major tobacco-growing states (Georgia, Kentucky, North Carolina, South Carolina, Tennessee, and Virginia), the mean state cigarette excise tax was disease (2) . Excise tax increases also can serve as a revenue source to fund and expand state tobacco control programs, further reducing tobacco use and disease (2, 4) . For example, if every state were to increase its cigarette excise tax by $1.00, even accounting for the resulting decrease in consumption, an estimated $9.1 billion in additional revenue would be generated each year in the United States (8) . Additionally, approximately 1 million premature smoking-caused deaths would be prevented, and 2.3 million children would not initiate smoking (8) .
Although Kentucky and North Carolina, the two major tobacco-growing states, did increase their cigarette excise taxes in 2009, the cigarette excise taxes in these states remain among the lowest in the country ( Figure 1 ). The individual cigarette excise tax rates in tobacco-growing and bordering southeastern states remain substantially lower than the rest of the country. These states typically have higher smoking rates and do not have strong tobacco control policies, such as comprehensive state smoke-free laws.*
The tax increases described in this report are a part of a general rise in cigarette excise taxes in the United States during the past decade (9) . The Institute of Medicine (IOM) noted in 2007 that recent cigarette excise tax increases had largely been in response to state budget shortfalls (2) , which also might explain the high number of states that increased their cigarette excise tax rates in 2009. The Healthy People 2010 objective (27-21a) † to increase the combined federal and mean state excise tax to at least $2.00 per pack also was achieved in 2009 ( Figure 2 ) (9) . In 2009, the combined federal and mean state cigarette excise tax * Data available at http://www.cdc.gov/tobacco/statesystem. † Available at http://www.healthypeople.gov/document/pdf/ volume2/27tobacco.pdf. (10) . In the first 15 years of funding, the $1.8 billion invested in the California tobacco control program resulted in an estimated $86 billion in savings in personal health-care expenditures (10) .
The findings in this report are subject to at least one limitation. The STATE system tracks only state-level data and does not include data on local (county, city, or other jurisdiction) taxes. Although not included in this analysis, approximately 460 communities impose a local tax on cigarettes, including New York City ($1.50 per pack) and Chicago-Cook County ($2.68 per pack). ¶ IOM recommends that states increase their cigarette excise tax and dedicate a portion of the revenue from these increases to fund comprehensive tobacco control programs at the state-specific level recommended by CDC (2) . The more that states spend on tobacco control programs, the greater the reductions in smoking, and the longer states invest in such programs, the greater the effect (4). With fully funded and sustained tobacco control programs complemented with strong tobacco control policies (e.g. cigarette excise tax increases, comprehensive smoke-free policies, and counter-marketing campaigns), IOM's best-case scenario for reducing smoking prevalence in the United States to 10% by 2025 would be attainable (2, 4) .
Cigarette price increases reduce the demand for cigarettes and thereby reduce smoking prevalence, cigarette consumption, and youth initiation of smoking (1, 2) . Excise tax increases are the most effective government intervention to increase the price of cigarettes (1), but cigarette manufacturers use trade discounts, coupons, and other promotions to counteract the effects of these tax increases (3) and appeal to price-sensitive smokers (4) . State cigarette minimum price laws, initiated by states in the 1940s and 1950s to protect tobacco retailers from predatory business practices (5, 6) , typically require a minimum percentage markup to be added to the wholesale and/or retail price. If a statute prohibits trade discounts from the minimum price calculation, these laws have the potential to counteract discounting by cigarette manufacturers (5) . To assess the status of cigarette minimum price laws in the United States, CDC surveyed state statutes and identified those states with minimum price laws in effect as of December 31, 2009. This report summarizes the results of that survey, which determined that 25 states had minimum price laws for cigarettes (median wholesale markup: 4.00%; median retail markup: 8.00%), and seven of those states also expressly prohibited the use of trade discounts in the minimum retail price calculation. Minimum price laws can help prevent trade discounting from eroding the positive effects of state excise tax increases and higher cigarette prices on public health (5) .
Cigarette prices are increased by several factors, including 1) federal and state excise taxes, which are applied per pack of 20 cigarettes, and 2) percentage markups by wholesalers and retailers (Table 1 ). All 50 states and the District of Columbia (DC) add a state excise tax to the manufacturer's invoice price (7); the result is referred to as the manufacturer base price. In certain states, state cigarette minimum price laws require the addition of a minimum percentage markup by the cigarette wholesaler to the base price, which results in the wholesale price. Most states with minimum price laws also require the addition of a minimum percentage markup by the cigarette retailer (6) . The result is the minimum retail price charged to the consumer. The cigarette minimum price laws in some states also expressly allow or prohibit trade discounts (i.e., reductions in price) from cigarette manufacturers to wholesalers or retailers in calculating the minimum retail price to consumers. Allowing trade discounts can partially reduce the price increases from taxes and minimum markups, which leads to a lower minimum price (Table 1) .
To conduct this survey, CDC researchers first reviewed eight known cigarette minimum price statutes (6) for Boolean search terms that would identify all other such statutes in a database of current statutes for all 50 states and DC. Identified statutes were then analyzed to determine 1) the minimum percentage markup that must be applied to cigarette prices by wholesalers and/or retailers, or the actual minimum price required by the law; 2) whether the statute allows or prohibits trade discounts to be considered in calculating minimum price; and 3) the state agency or officer with regulatory enforcement authority. To ensure that all state cigarette minimum price laws were identified, researchers also reviewed all pricing laws in those states that appeared not to have a minimum price law. When a statute indicated that wholesalers must apply a minimum percentage markup for transportation costs, that percentage was included in the wholesale minimum markup.
As of December 31, 2009, 25 states* had statutory minimum prices for cigarettes ( Table 2 ). The minimum percentage by which these states required markup on the wholesale price of cigarettes ranged from 2.00% in DC, Louisiana, and Mississippi to 6.50% in Connecticut. The median required wholesale percentage markup among the 25 states was 4.00%. The minimum percentage by which states required a markup on the retail price of cigarettes ranged from 6.00% in six states (Alaska, Louisiana, Mississippi, Oklahoma, Pennsylvania, and Wisconsin) to 25.00% in Massachusetts. The median required retail percentage markup among the 25 states was 8.00%. The minimum price laws in Rhode Island and Washington did not require a percentage markup for either wholesale or retail; instead, the state statutes set the minimum price as the "replacement cost" and "actual price paid," respectively. Additionally, Delaware was the only state with a minimum price for wholesalers but not for retailers, and Tennessee was the only state with a minimum price for retailers but not for wholesalers.
State Cigarette Minimum Price Laws -United States, 2009
* For this report, DC is included among states.
Seven of the 25 states with minimum price laws (Arkansas, DC, Minnesota, Montana, Nebraska, New York, and Pennsylvania) expressly prohibit trade discounts in calculating the minimum retail price for cigarettes ( Table 2) . Fourteen of the states expressly allow trade discounts to be taken into account when calculating minimum price. Cigarette minimum price statutes in four other states (Iowa, Massachusetts, Rhode Island, and Washington) neither expressly prohibit nor expressly allow trade discounts in calculating the minimum retail price for cigarettes. 
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Editorial Note
Increasing the price of tobacco products is an evidence-based tobacco control strategy that can produce substantial long-term improvements in health (1) . Cigarette tax increases are the most effective and direct way that governments can increase the price of cigarettes (1, 2) . However, cigarette manufacturers spent $12.5 billion on marketing and promotional expenditures in 2006, 74% of which was spent to reduce the price of cigarettes at the point of sale (8) . Although 15 states increased their cigarette excise tax rates in 2009 (7), the impact of those increases on consumer prices might have been blunted by trade discounts from cigarette manufacturers. Cigarette minimum price laws, which were initiated by states in the 1940s and 1950s to protect tobacco retailers from predatory business practices by large retailers (e.g., selling an item at a price below cost to attract more customers into a store) (5, 6) , have the potential to counteract trade discounting. Although excise tax increases remain the most direct way for states to increase the price of cigarettes (1), creating or strengthening minimum price laws is another way to increase cigarette prices.
Cigarette minimum price laws also have the potential to increase the consumer price of cigarettes in states with low cigarette excise tax rates (6) . Currently, of the states with the 10 lowest state excise taxes, only one state (Louisiana) has a minimum price law. States with average-to-high excise tax rates also might benefit from minimum price laws, by using them to mitigate the effect discounting by cigarette manufacturers has on cigarette prices. Currently, of the 10 states with the highest excise taxes, eight states (all but Hawaii and Vermont) have a minimum price law. Although minimum price laws that expressly prohibit trade discounts from being considered when calculating minimum price can help preserve the beneficial public health impact of tax increases (6), additional laws might be necessary to prohibit all retail price promotions (e.g., coupons or two-for-one offers) that can decrease cigarette retail prices to consumers.
The findings in this report are subject to at least three limitations. First, this survey only includes states with minimum price laws that apply specifically to cigarettes. At least seven other states † have general minimum price laws (9) that apply to other types More research is needed to determine how cigarette minimum price laws affect consumer prices and state revenue from tobacco products (5) . State tobaccocontrol programs can partner with state tax departments or other state agencies with regulatory enforcement authority over cigarette minimum price laws to determine how these laws are enforced. The programs also can identify gaps in the law that might be used by cigarette manufacturers and retailers to reduce cigarette prices (e.g., remote sales via the Internet and mail order, direct sales from manufacturers to consumers, or coupons and other direct-to-consumer discounts).
What is already known on this topic?
Cigarette minimum price laws were developed by states in the 1940s and 1950s to protect tobacco retailers from predatory business practices, but these laws also have the potential to increase cigarette prices and to counteract price discounting by cigarette manufacturers.
What is added by this report?
A survey of all state cigarette minimum price laws indicated that 25 states had cigarette minimum price laws at the end of 2009, and seven of those states prohibited using trade discounts in the calculation of minimum prices.
What are the implications for public health practice?
State tobacco control programs can partner with the state tax agencies and others to determine how these laws are enforced and to identify gaps that might be used by cigarette manufacturers to reduce cigarette prices.
On October 19, 2009, clinicians from Kentucky contacted CDC regarding a suspected case of rabies in a man from Indiana aged 43 years. This report summarizes the patient's clinical presentation and course, the subsequent epidemiologic investigation, and, for the first time, provides infection control recommendations for personnel performing autopsies on decedents with confirmed or suspected rabies infection. Before the patient's death on October 20, a diagnosis of rabies was suspected based on the history of acute, progressive encephalitis with unknown etiology. Preliminary serology results on antemortem serum samples detected rabies virus-specific antibodies. Because local pathologists were concerned about the biosafety risk posed by infectious aerosols at autopsy and potential contamination of autopsy facilities, the Kentucky Department for Public Health (KDPH) asked CDC staff members to travel to Kentucky and perform an autopsy to confirm the diagnosis and assist with the epidemiologic investigation. Testing of autopsy samples was conducted at CDC and detected rabies virus antigens in brainstem and cerebellum. Rabies viral RNA was isolated and typed as a variant common to the tricolored bat (Perimyotis subflavus). Although rabies virus transmission from organ or tissue transplant has been documented rarely (1,2), transmission of rabies virus to persons performing autopsies has not been reported. Autopsies can be performed safely on decedents with confirmed or suspected rabies using careful dissection techniques, personal protective equipment, and other recommended precautions.
Case Report
On October 5, 2009, a previously healthy man from Indiana aged 43 years visited an employee health clinic with fever and cough. His vital signs and physical examination were unremarkable except for coarse rales on lung auscultation. The clinician made a diagnosis of bronchitis, prescribed antibiotics, and asked the patient to return the following day. At this follow-up appointment, the patient reported worsening fever and chills, as well as new chest pain and left arm numbness; he also exhibited decreased grip strength of the left hand. An electrocardiogram showed no evidence of cardiac ischemia. Later that day, an evaluation at a local emergency department was similarly unrevealing, and the patient was given narcotics and muscle relaxants for presumed musculoskeletal pain and discharged home.
On October 7, the patient returned to the same ED, where he was noted to have akathisia and motor restlessness thought to be side effects from the muscle relaxant. The ED physician advised admission to the hospital, but the patient returned home. Upon follow-up the next day with a primary-care physician, the patient had prominent muscle fasciculations, fever, tachycardia, and hypotension. Given these signs, the physician was concerned about the possibility of sepsis and admitted him to the hospital.
After admission, the patient's mental status deteriorated rapidly, and he underwent endotracheal intubation for airway protection. On October 9, he was transferred to a referral hospital in the neighboring state of Kentucky. A lumbar puncture yielded cerebrospinal fluid (CSF) with glucose of 72 mg/dL (normal: 40-70 mg/dL), protein 140 mg/dL (normal: 15-45 mg/dL), 3 red blood cells/mm 3 (normal: 0-2 cells/mm 3 ), and 38 white blood cells /mm 3 (normal: 0-5 cells/mm 3 ); differential showed 99% lymphocytes and 1% monocytes. During October 9-19, no etiology for the patient's disease was identified, and his hospital course became complicated by bradycardia, hypotension, rhabdomyolysis, and renal failure requiring hemodialysis. Results of a magnetic resonance image of the brain and a brain perfusion study were normal. Bacterial and fungal cultures of CSF, in addition to laboratory tests for West Nile virus, herpes simplex virus, influenza, and human immunodeficiency virus, were negative.
On October 19, diagnostic testing for rabies was requested, and samples of the patient's serum, saliva, and a nuchal skin biopsy were sent to CDC for analysis. However, on October 20, while these tests were pending, the patient's physical examination, electroencephalogram, and apnea testing all indicated brain death. Ventilatory support was withdrawn, and the patient died on October 20.
Postmortem Findings
On October 22, testing at CDC indicated rabies specific immunoglobulin G (1:2,048) and immunoglobulin M (1:512) antibodies in serum by the indirect fluorescent-antibody (IFA) assay. Subsequent testing detected rabies virus neutralizing antibodies (0.44 IU/mL) in serum by rapid fluorescent focus Human Rabies -Kentucky/Indiana, 2009 inhibition test (RFFIT). The formalin-fixed nuchal skin biopsy specimen tested negative for viral antigens by immunohistochemistry (IHC). On October 27, a CSF sample collected on October 11 and located postmortem was sent to CDC and also tested negative for rabies antibodies by IFA and RFFIT. The family requested an autopsy, but pathologists at the referral hospital were concerned about the biosafety risk posed by infectious aerosols at autopsy and potential contamination of autopsy facilities. Attempts to identify other personnel and facilities willing to perform the autopsy, including several tertiary-care and teaching centers in Kentucky, Indiana, and Tennessee, were unsuccessful because of similar concerns. In response to a request for assistance from KDPH, CDC staff members traveled to Kentucky and performed an autopsy limited to the head to collect tissue specimens for diagnostic evaluation.
At autopsy, the brain weighed 1,610 g (normal: 1,300-1,400 g) and showed markedly congested and hemorrhagic leptomeninges ( Figure 1 ). Histopathologic examination revealed encephalomyelitis and abundant neuronal cytoplasmic inclusions (Negri bodies) ( Figure 2 ). Rabies virus antigens were detected in multiple samples of fresh central nervous system (CNS) tissue by direct fluorescent antibody (DFA) testing and in formalin-fixed CNS tissues by IHC ( Figure 2 ). Viral RNA was detected in the patient's saliva collected antemortem and CNS tissues collected at autopsy by reverse transcriptionpolymerase chain reaction and was typed as a variant common to the tricolored bat (Perimyotis subflavus).
Public Health Investigation
The referral hospital and CDC notified KDPH and the Indiana State Department of Health (ISDH) about the case on October 21, the day before rabies virus-specific antibodies were found in the patient's serum. Beginning on October 23, ISDH, with the assistance of the local health department and, later, CDC, began interviewing the patient's close contacts, including family, friends, coworkers, and health-care personnel, to clarify his exposure history and determine whether rabies postexposure prophylaxis (PEP) should be recommended to any of the contacts. The investigation identified no specific source of rabies virus exposure. However, the patient, who worked as a mechanic and lived in a farming community in southern Indiana, had mentioned to his friends that he had seen a bat in late July after removing a tarpaulin from a tractor adjacent to his residence. He had not mentioned a bite or a nonbite exposure associated with this or any other incident.
The investigation identified 159 persons who had interaction with the patient 2 weeks before or during the 2-week duration of his illness. All of these 159 persons were counseled about the potential risks associated with rabies virus exposure. Investigators distributed a handout detailing basic information about rabies, how the virus is transmitted, and what constitutes an exposure. Of the 159 persons, 147 were health-care providers who treated the patient during his visits to four medical facilities, or who transported him between hospitals. Two family members, two coworkers, and 14 health-care providers were identified as having been potentially exposed to saliva from the patient. All 18 were recommended to receive rabies PEP, and all completed the vaccination series according to Advisory Committee for Immunization Practices (ACIP) recommendations (3, 4) . To date, none of the 159 persons has developed rabies. 
Editorial Note
The case described in this report represents the first rabies death in an Indiana resident since 2006 and only the second such death since 1959. Including this case, a total of 31 cases of human rabies have been reported in the United States since 2000. Of these, 14 (45%) were diagnosed postmortem, reinforcing the need to consider rabies in all cases of acute progressive encephalitis of unknown etiology. Human rabies cases in the United States might be underreported because of lack of recognition and lack of confirmation by diagnostic testing. When rabies is suspected, antemortem diagnosis requires testing of serum, saliva, CSF, and a nuchal skin biopsy.
The postmortem diagnosis of rabies is made by examination of tissue from the brain (e.g., medulla, cerebellum, and hippocampus). Autopsies fulfill an important function by diagnosing cases of rabies and furthering understanding of the disease. By providing a diagnosis for deceased patients with suspected but unconfirmed rabies, or for patients in whom the disease was never suspected clinically, autopsies can 1) aid the public health investigation, 2) help raise public awareness of rabies associated with specific exposures, 3) emphasize the importance of seeking medical evaluation after such an exposure occurs, and 4) add to knowledge about current human rabies incidence. In patients with confirmed rabies, autopsies provide information about pathogenesis that might be relevant to investigations of treatment.
Although contact with decedents with confirmed or suspected rabies can cause anxiety, no confirmed case of rabies has ever been reported among persons performing postmortem examinations of humans or animals. Even from living patients with rabies, human-to-human transmission has been documented only rarely, in cases of organ or tissue transplantation (1,2). Aerosol transmission of rabies virus has never been well documented outside of a research laboratory setting (5) . Both CDC and the World Health Organization (WHO) have stated that the infection risk to health-care personnel from human rabies patients is no greater than from patients with other viral or bacterial infections. In addition, rabies PEP is available for exposed personnel. Nevertheless, because of the nearly universal fatal outcome from rabies, both CDC and WHO recommend that all personnel working with rabies patients or decedents adhere to recommended precautions (3, 6) .
Even the minimal risk for rabies virus transmission at autopsy can be reduced by using careful dissection techniques and appropriate personal protective equipment, including an N95 or higher respirator, full face shield, goggles, gloves, complete body coverage by protective wear, and heavy or chain mail gloves to help prevent cuts or sticks from sharp instruments or bone fragments (Box). Aerosols should be minimized by using a handsaw rather than an oscillating saw, and by avoiding contact of the saw blade with brain tissue while removing the calvarium. Ample use of a 10% solution of sodium hypochlorite for disinfection is recommended both during and after the procedure to ensure decontamination of all exposed surfaces and equipment. Participation in the autopsy should be limited to persons directly involved in the procedure and collection of specimens. Previous vaccination against rabies is not required for If not prevented by administration of postexposure prophylaxis, the rabies virus causes an acute progressive viral encephalitis that is almost always fatal.
What is added by this report?
In October 2009, a man from Indiana aged 43 years died of rabies; the diagnosis was made postmortem and confirmed by samples collected at autopsy.
Recognizing and diagnosing human rabies is critical in initiating an appropriate clinical and public health response, furthering understanding of the disease, and implementing appropriate prevention and control measures; autopsies can be performed safely on decedents with confirmed or suspected rabies using careful dissection techniques, personal protective equipment, and other recommended precautions.
persons performing such autopsies. PEP of autopsy personnel is recommended only if contamination of a wound or mucous membrane with patient saliva or other potentially infectious material (e.g., neural tissue) occurs during the procedure (3, 7, 8) . The case described in this report highlights the need to educate pathologists and other hospital personnel about appropriate rabies infection control procedures so that autopsies can be performed safely in cases of confirmed or suspected human rabies.
BOX. CDC recommendations for performing autopsies of humans with confirmed or suspected rabies
• Use personal protective equipment, including an N95 or higher respirator, full face shield, goggles, and gloves, as well as complete body coverage with protective wear.
• Use heavy or chain mail gloves to help prevent cuts or sticks from cutting instruments or bone fragments.
• Minimize aerosol generation by using a handsaw rather than an oscillating saw and avoiding contact of the saw blade with brain tissue while removing the calvarium.
• Limit participation to those directly involved in the procedure and collection of specimens.
• Use ample amounts of a 10% sodium hypochlorite solution during and after the procedure to ensure decontamination of all exposed surfaces and equipment • Previous vaccination against rabies is not required for persons performing such autopsies, and postexposure prophylaxis of autopsy personnel is recommended only if contamination of a wound or mucous membrane with patient saliva or other potentially infectious material (e.g., neural tissue) occurs during the procedure.
MMWR Vol. 59, No. 12
In the report, "Interim Results: Influenza A (H1N1) 2009 Monovalent and Seasonal Influenza Vaccination Coverage Among Health-Care Personnel -United States, August 2009-January 2010," in the second paragraph on page 357, the second and third sentences should read as follows: "The panel, maintained by Knowledge Networks, Inc., consists of persons recruited using address-based sampling and random-digit-dialing sampling methodology. For the random-digit-dialing sampling, Knowledge Networks uses quality standards comparable to those of the National Immunization Survey." In addition, the link in the footnote for that paragraph should be: http://www.knowledgenetworks.com/ ganp/docs/knowledgepanel(r)-design-summarydescription.pdf. In the first paragraph on p. 360, the second sentence of the paragraph should read as follows: "An employer recommendation was associated with an almost twofold higher coverage rate for seasonal influenza vaccination compared with the rate among HCP whose employers neither required nor recommended seasonal vaccination (relative risk [RR] = 1.7; p<0.001); an employer requirement was associated with a rate almost threefold higher (RR = 2.6; p<0.001)." Finally, in Table 2 on p. 361, the percentage receiving seasonal influenza vaccine among facilities that did not have a policy that required or recommended such vaccination should read 37.8%, with a 95% confidence interval of (27.9-47.7). Table II. † † Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, † † † † There were no cases of Viral Hemorrhagic Fever during week one. See Table II for Dengue Hemorrhagic Fever. American 9  13  31  170  231  Delaware  -1  3  9  5  6  18  37  234  214  -0  1  2  1  District of Columbia  -0  2  5  13  47  45  88  483  748  -0  1  -1  Florida  38  36  59  438  466  198  403  476  4,570  5,365  7  4  10  50  76  Georgia  12  11  67  223  199  1  200  415  204  3,509  1  3  9  43  52  Maryland  §  4  5  12  67  65  -123  241  933  1,434  1  1  6  10  27  North Carolina  N  0  0  N  N  -197  377  -3,541  -0  17  17  20  South Carolina  §  2  2  8  25  27  117  161  412  2, -7  19  75  80  227  887 1,553  8,036  11,822  3  2  10  38  36  Arkansas  §  -3  9  21  25  120  84  139  990  1,165  -0  3  4  8  Louisiana  -1  7  29  40  -156  343  910  2,660  -0  2  7  7  Oklahoma  -3  10  25  15  107  64  613  1,087  618  3  1  7  25  20  Texas  §  N  0  0  N  N  -562  951  5,049  7,379  -0  2  2  1   Mountain  18  29  61  363  292  74  163  255  1,606  2,269  1  5  15  94  83  Arizona  1  4  11  37  42  23  58  108  390  670  -1  9  36  31  Colorado  13  9  26  172  87  13  40  99  595  688  1  1  6  25  22  Idaho  §  4  4  10  51  29  4  2  8  22  25  -0  1  2  1  Montana  §  -2  11  28  24  2  1  6  34  26  -0  1  -1  Nevada  §  -1  10  15  7  32  26  94  376  523  -0  2  4  6  New Mexico  §  -1  8  14  26  -21  36  134  236  -1  5  13  12  Utah  -5  13  32  62  -5  13  48  88  -1  4  9  10  Wyoming  §  -1  5  14  15  -1  7  7  13  -0  2  5  -Pacific  36  53  159  577  518  345  531  626  6,677  8,106  1  2  9  28  43  Alaska  -2  7  21  16  -20  36  282  218  -0  3  8  3  California  23  33  60  364  375  291  439  545  5,656  6,732  -0  4  -11  Hawaii  -0  2  -6  -13  24  163  151  -0  3  -16  Oregon  4  9  18  119  80  -18  43  106  318  1  1  4  18  12  Washington  9  7  106  73  41  54  39  64  470  687  -0  4  2  1 American Samoa Table I . § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 10  36  61  314  473  26  56  121  579  939  7  16  43  163  221  New England  -2  5  12  28  -1  4  9  14  -1  5  6  14  Connecticut  -0  2  7  7  -0  3  3  3  -1  4  6 10 1  8  14  71  115  12  15  35  169  299  1  3  12  37  48  Delaware  -0  1 Florida  1  3  9  28  59  8  5  13  70  91  1  1  4  13  6  Georgia  -1  4  9  17  3  3  7  40  50  -0  2  1  11  Maryland  †  -0  3  2  14  -1  6  17  37  -1  3  6  13  North Carolina  -0  7  8  12  -0  12  2  87  -0  10  9  6  South Carolina  †  -1  4  13  7  -1  4  9  5  -0  1  --Virginia  †  -1  3  7  6  1  2  13  23  15  -0  2  4  5  West Virginia  -0  2  1  --0  19  8  14  -0  3  4  7 E.S. Central  -1  3  11  11  2  7  13  74  101  1  2  5  23  34  Alabama  †  -0  2  3  1  -1  5  18  31  -0  2  1  4  Kentucky  -0  2  5  1  -2  6  26  20  1  1  5  20  18  Mississippi  -0  1  -5  -0  3  4  7  -0  0  --Tennessee  †  -0  2  3  4  2  2  6  26  43  -0  3  2  12 W.S. Central  -3  18  33  45  6  9  26  61  130  2  1  6  12  13  Arkansas  †  -0  2  -4  -1  4  2  12  -0  1  -1  Louisiana  -0  1  1  2  -0  3  12  16  -0  1  1  3  Oklahoma  -0  3  -1  2  2  8  10  24  2  0  4  5  1  Texas  †  -3  18  32  38  4  6  20  37  78  -0  4  6  8   Mountain  3  3  9  38  29  -2  5  21  41  1  1  4  10  18  Arizona  2  1  5  25  13  -0  3  8 American Samoa 9  11  22  85  89  8  68  253  415  560  5  6  16  70  96  Delaware  -0  5  3  --13  65  113  105  -0  1  1  1  District of Columbia  -0  2  -1  -0  5  1  2  -0  1  1  5  Florida  3  4  10  35  38  2  2  11  16  7  3  2  7  37  25  Georgia  1  1  4  10  17  -0  5  1  13  -1  5  2  15  Maryland  †  3  3  12  19  14  4  29  134  171  331  2  1  13  13  28  North Carolina  -0  5  1  13  -0  14  12  14  -0  3  5 Texas  †  -1  8  12  14  1  4  43  5  8  -1  30  31  4   Mountain  3  3  8  26  26  -1  4  4  5  -0  6  7  3  Arizona  1  1  5  13  9  -0 -1  8  27  25  13  68  704  537  336  2  0  13  10  10  Arkansas  §  -0  2  2  5  -5  30  18  39  -0  10  6  6  Louisiana  -0  3  5  8  -0  8  7  29  -0  0  --Oklahoma  -0  7  12  2  -0  32  3  9  2  0  13  4  4  Texas  §  -1  7  8  10  13  60  674  509  259  -0  1  --Mountain  1  1  4  14  25  6  16  39  158  280  2  1  6  13  31  Arizona  -0  2  5  4  1  5  16  46  50  N  0  0  N  N  Colorado  -0  3  3  9  5  3  10  26  70  -0  0  --Idaho  §  -0  1  1  5  -1  19  43  22  -0  1 0  1  2  1  -1  6  24  29  -0  3  3  11  Utah  -0  1  -1  -2  11  12  99  -0  2  --Wyoming  §  -0  2  -1  -0  5  1  3  2  0  4  9  10   Pacific  4  3  17  48  54  3  24  46  106  203  4  4  13  34  40  Alaska  -0  2  -2  -0  4  5  24  -0  2  8  10  California  4  2  10  37  28  2  11  25  11  73  4  3  11  22  30  Hawaii  -0  1  -1  -0  3  -7  -0  0  --Oregon  -0  4  7  17  -5  12  61  56  -0  3  4  -Washington  -0  6  4  6  1  4  39  29 United States  263  913 1,443  5,401  8,087  22  84  174  379  720  114  278  504  2,533  3,731  New England  -31  91  129  727  -3  30  10  89  -4  27  18  89  Connecticut  -0  66  66  429  -0  5  5  67  -0  11  11  43  Maine  §  -2  7  14  23  -0  3  ---0  2  2  2  Massachusetts  -20  47  -202  -2  7  -11  -3  27  -37  New Hampshire  -3  44  24  37  -0  3  5  9  -0  4  3  1  Rhode Island  §  -2  12  17  24  -0  26  ---0  7  1  4  Vermont  §  -1  5  8  12  -0  3  -2  -0  1 American Samoa - 
Errata
W.S. Central  -0  3  1  --1  25  5  6  Arkansas  §  -0  0  ---0  14  -1  Louisiana  -0  0  ---0  1  --Oklahoma  -0  3  ---0  24  1  1  Texas  §  -0  1  1  --0  11  4  4   Mountain  -0  2  3  1  -0  6  12  2  Arizona  -0  2  3  1  -0  6 12 -66  261  623  1,432  -0  19  ---0  6  --Arkansas  §  -0  23  26  41  -0  1  ---0  0  --Louisiana  -1  7  19  20  -0  2  ---0  4  --Oklahoma  N  0  0  N  N  -0  2  ---0  2  --Texas  §  -65  245  578  1,371  -0  16  ---0  4  --Mountain  5  20  62  303  577  -0  12  ---0  17  --Arizona  -0  0  ---0  4  ---0  2  --Colorado  §  -8  22  108  202  -0  7  ---0 Table IV , which appears quarterly. † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I . § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). ¶ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenzaassociated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. 
